세계의 색전술 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 제품별, 적응증별, 순서별, 최종 사용자별, 지역별, 경쟁별(2020-2030년)
Embolotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Indication, By Procedure, By End User, By Region & Competition, 2020-2030F
상품코드:1785352
리서치사:TechSci Research
발행일:2025년 08월
페이지 정보:영문 190 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 색전술 시장 규모는 2024년에 36억 7,000만 달러가 되고, 2030년까지의 CAGR은 8.35%로, 예측 기간 중에 눈부신 성장이 예측되고 있습니다.
색전술은 표적 부위로의 혈류를 선택적으로 제한하는 최소 침습적 치료법입니다. 이 치료법은 비정상적인 혈관을 막아 출혈을 효과적으로 제어하거나 중단하기 위해 사용되는 혈관 내 시술입니다. 심각한 출혈이 발생한 긴급한 경우, 색전술은 침습적 수술의 실용적인 대안으로 등장했습니다. 이 치료 방법은 널리 인정받고 있으며, 전 세계의 다양한 임상 환경에서 중재적 방사선과 의사에 의해 시행되고 있습니다. 색전술의 용도는 특히 양성 전립선 비대증에 대한 전립선 동맥 색전술(PAE) 및 체중 감량을 위한 위 동맥 색전술(GAE)과 같은 최신기술 시술에서 크게 확대되었습니다. 이 두 시술은 각각의 질환에 대한 효과적인 치료 옵션으로 사용됩니다. 특히 PAE는 BPH로 인한 하부 요로 증상(LUTS)을 치료하기 위해 전 세계적으로 매년 800건 이상의 시술이 시행되고 있습니다. 색전술은 골관절염, 오십견, 과다 사용으로 인한 부상 등 근골격계 만성 통증의 관리에 사용됩니다. 자궁 근종 치료에 대한 이 요법의 적용은 전 세계적으로 약 85%의 성공률을 보였습니다. 이 요법은 특정 유형의 암, 특히 간암의 치료에 활용됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
36억 7,000만 달러
시장 규모 : 2030년
58억 9,000만 달러
CAGR(2025-2030년)
8.35%
급성장 부문
색전제
최대 시장
북미
시장 성장 촉진요인
증가하는 목표 환자 인구
주요 시장 과제
엄격한 규제
주요 시장 동향
인수 및 협력의 증가
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 목소리
제5장 세계의 색전술 시장 전망
시장 규모와 예측
금액별
시장 점유율 및 예측
제품별(색전제, 마이크로카테터)
적응증별(종양학, 혈관학, 동맥류학, 비뇨기학, 신장학)
순서별(TACE, TARE)
최종 사용자별(병원, 클리닉, 외래수술센터(ASC))
지역별
기업별(2024년)
시장 맵
제6장 북미의 색전술 시장 전망
시장 규모와 예측
시장 점유율 및 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 색전술 시장 전망
시장 규모와 예측
시장 점유율 및 예측
유럽 : 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 색전술 시장 전망
시장 규모와 예측
시장 점유율 및 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 색전술 시장 전망
시장 규모와 예측
시장 점유율 및 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 색전술 시장 전망
시장 규모와 예측
시장 점유율 및 예측
중동 및 아프리카 : 국가별 분석
남아프리카
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
합병과 인수
제품 출시
최근 동향
제13장 Porter's Five Forces 분석
업계 내 경쟁
신규 진입의 가능성
공급자의 힘
고객의 힘
대체품의 위협
제14장 경쟁 구도
Medtronic, PLC.
Microport Scientific
Boston Scientific Corporation
Stryker Corporation
Terumo Corporation
Penumbra, Inc.
Sirtex(CDH)
Johnson & Johnson
Abbott Laboratories Inc.
Balt Group(Balt Extrusion SAS)
제15장 전략적 제안
제16장 기업 소개와 면책사항
HBR
영문 목차
영문목차
Global Embolotherapy Market was valued at USD 3.67 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.35% through 2030. Embolotherapy is a minimally invasive treatment that selectively restricts blood flow to targeted areas. It is an endovascular procedure utilized to occlude abnormal blood vessels, effectively controlling or ceasing bleeding. In urgent cases of severe hemorrhage, Embolotherapy has emerged as a viable alternative to invasive surgery. This treatment option has gained widespread recognition and is performed globally by interventional radiologists in various clinical settings. The applications of Embolotherapy have expanded significantly, particularly in cutting-edge procedures such as prostatic artery embolization (PAE) for benign prostatic hyperplasia and gastric artery embolization (GAE) for weight loss. Both of these procedures serve as effective treatment options for their respective conditions. PAE, in particular, is performed worldwide in over 800 procedures annually to address lower urinary tract symptoms (LUTS) caused by BPH. Embolotherapy is employed in the management of chronic pain conditions in the musculoskeletal system, including osteoarthritis, frozen shoulder, and overuse injuries. Its application in treating uterine fibroids has shown a success rate of approximately 85% globally. It is utilized in the treatment of specific types of cancer, notably liver cancer.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 3.67 Billion
Market Size 2030
USD 5.89 Billion
CAGR 2025-2030
8.35%
Fastest Growing Segment
Embolic Agents
Largest Market
North America
Key Market Drivers
Growing Target Patient Population
Cardiovascular disease (CVD) is a significant target ailment, and its importance and high prevalence have made it a focal point for research into successful and effective treatments. For instance, in May 2023, a study in Stroke, the American Stroke Association's leading journal, detailed a groundbreaking in-utero surgery to treat a fetal vein of Galen malformation-a rare, life-threatening cerebral vascular disorder. This successful intervention highlights the expanding target patient population for embolotherapy, driven by advances in prenatal diagnostics and treatment. As awareness and early detection grow, demand for innovative embolization solutions in both pediatric and fetal care is expected to rise. In 2017, peripheral vascular diseases affected over 200 million individuals worldwide. According to the same source, the prevalence of these diseases rises with age, with a prevalence rate of over 20% in those aged 80 and above. The increasing demand for Embolotherapy devices will be driven by the notable success rate and low postoperative complication rate associated with Embolotherapy procedures, coupled with the rising incidence of liver cancer and hepatocellular cancer. Liver cancer ranks as the fifth most common cancer in men and the ninth most common cancer in women, with over 840,000 new cases diagnosed worldwide in 2018 (source: World Cancer Research Fund). The kidney cancer incidence rates in the United Kingdom have witnessed a significant 42% increase over the past decade, with males experiencing a 38% incidence rate and females a 44% rate.
Key Market Challenges
Stringent regulations
Artificial embolization devices, including permanent microspheres used as artificial emboli (AED), are classified as medical devices. These devices function by physically closing vessels and are regulated as Class II vascular and neurovascular embolization devices in the United States. In the European Union, they are classified as Class IIB bland embolization devices under the medical device directive MDD 93/42/EEC. PVA particles have been used for over 40 years as a comparison device, serving as the basis for approval or authorization of later next-generation items due to their demonstrated general embolization of vessels.
Key Market Trends
Increasing Acquisitions and Collaborations
Increasing acquisitions and collaborations can indeed contribute to an increased demand for embolotherapy in the future. Collaborative efforts within the healthcare industry often lead to enhanced research, development, accessibility, and awareness of medical procedures like embolotherapy. Collaborations between pharmaceutical companies, medical device manufacturers, and research institutions can accelerate the research and development of new and improved embolotherapy techniques, devices, and materials. This can lead to innovations that increase the effectiveness and safety of embolotherapy procedures. Acquisitions and collaborations bring together the expertise of different entities. This multidisciplinary approach can lead to the creation of comprehensive and integrated embolotherapy solutions that cater to diverse patient needs.
Key Market Players
Medtronic, PLC
Microport Scientific Corp
Boston Scientific Corporation
Stryker Corporation
Terumo Corporation
Penumbra, Inc.
Sirtex (CDH)
Johnson & Johnson
Abbott Laboratories Inc.
Balt Group (Balt Extrusion SAS
Report Scope:
In this report, the Global Embolotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Embolotherapy Market, By Product:
Embolic Agents
Microspheres
Liquid Embolic Agents
Coil
Microcatheters
Embolotherapy Market, By Indication:
Oncology
Vascular
Aneurysm
Urology
Nephrology
Embolotherapy Market, By Procedure:
TACE
TARE
Embolotherapy Market, By End User:
Hospital
Clinics
Ambulatory Surgery Centres
Embolotherapy Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Embolotherapy Market.
Available Customizations:
Global Embolotherapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Embolotherapy Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Embolic Agents, Microcatheters)
5.2.1.1. By Embolic Agents (Microspheres, Liquid Embolic Agents, Coil)
5.2.2. By Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology)
5.2.3. By Procedure (TACE, TARE)
5.2.4. By End User (Hospital, Clinics, Ambulatory Surgery Centers)
5.2.5. By Region
5.2.6. By Company (2024)
5.3. Market Map
6. North America Embolotherapy Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Indication
6.2.3. By Procedure
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Embolotherapy Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Indication
6.3.1.2.3. By Procedure
6.3.1.2.4. By End User
6.3.2. Canada Embolotherapy Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Indication
6.3.2.2.3. By Procedure
6.3.2.2.4. By End User
6.3.3. Mexico Embolotherapy Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Indication
6.3.3.2.3. By Procedure
6.3.3.2.4. By End User
7. Europe Embolotherapy Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Indication
7.2.3. By Procedure
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Embolotherapy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Indication
7.3.1.2.3. By Procedure
7.3.1.2.4. By End User
7.3.2. United Kingdom Embolotherapy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Indication
7.3.2.2.3. By Procedure
7.3.2.2.4. By End User
7.3.3. Italy Embolotherapy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Indication
7.3.3.2.3. By Procedure
7.3.3.2.4. By End User
7.3.4. France Embolotherapy Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Indication
7.3.4.2.3. By Procedure
7.3.4.2.4. By End User
7.3.5. Spain Embolotherapy Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Indication
7.3.5.2.3. By Procedure
7.3.5.2.4. By End User
8. Asia-Pacific Embolotherapy Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Indication
8.2.3. By Procedure
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Embolotherapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Indication
8.3.1.2.3. By Procedure
8.3.1.2.4. By End User
8.3.2. India Embolotherapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Indication
8.3.2.2.3. By Procedure
8.3.2.2.4. By End User
8.3.3. Japan Embolotherapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Indication
8.3.3.2.3. By Procedure
8.3.3.2.4. By End User
8.3.4. South Korea Embolotherapy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Indication
8.3.4.2.3. By Procedure
8.3.4.2.4. By End User
8.3.5. Australia Embolotherapy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Indication
8.3.5.2.3. By Procedure
8.3.5.2.4. By End User
9. South America Embolotherapy Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Indication
9.2.3. By Procedure
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Embolotherapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Indication
9.3.1.2.3. By Procedure
9.3.1.2.4. By End User
9.3.2. Argentina Embolotherapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Indication
9.3.2.2.3. By Procedure
9.3.2.2.4. By End User
9.3.3. Colombia Embolotherapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Indication
9.3.3.2.3. By Procedure
9.3.3.2.4. By End User
10. Middle East and Africa Embolotherapy Market Outlook
